A Study to Evaluate 2 Doses Of Oral Administration Of Laquinimod Compared to Interferon ß-1a Administered by Injection in Participants With Relapsing Remitting Multiple Sclerosis (RRMS)

Status:
Withdrawn

Trial end date:
2014-03-01

Target enrollment:

Participant gender:

The purpose of the study is to assess the efficacy, safety, and tolerability of two doses of laquinimod compared to Avonex®

Phase 3

Teva Branded Pharmaceutical Products R&D, Inc.
Teva Pharmaceutical Industries

Interferon beta-1a
Interferon-beta
Interferons